Open AccessIntralesional purified protein derivative of tuberculin versus intralesional mycobacterium W vaccine in treatment of recalcitrant extragenital warts: A randomized, single-blinded, comparative study
Author(s) -
Alpana Mohta,
SureshKumar Jain,
RajeshDutt Mehta,
Aakanksha Arora
Publication year - 2022
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_521_21
Subject(s) - medicine , tuberculin , dermatology , adverse effect , vaccination , erythema , purified protein derivative , randomized controlled trial , bcg vaccine , population , tuberculosis , surgery , immunology , pathology , environmental health
Of late, immunotherapy has emerged as a promising therapeutic modality for the treatment of recalcitrant and difficult to treat warts. Purified protein derivative of tuberculin (PDD) and mycobacterium w (Mw) vaccine hold promising prospects for the treatment of verruca, especially in a country like ours where a majority of the population is already sensitized to mycobacterium tuberculosis both due to disease endemicity and Bacillus Calmette-Guérin (BCG) vaccination.